F
Fiorenza De Gregorio
Researcher at University of Naples Federico II
Publications - 10
Citations - 123
Fiorenza De Gregorio is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Myeloid leukemia & Ponatinib. The author has an hindex of 5, co-authored 10 publications receiving 77 citations.
Papers
More filters
Journal ArticleDOI
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Giovanni Caocci,Olga Mulas,Elisabetta Abruzzese,Luigiana Luciano,Alessandra Iurlo,Immacolata Attolico,Fausto Castagnetti,Sara Galimberti,Nicola Sgherza,Massimiliano Bonifacio,Mario Annunziata,Antonella Gozzini,Ester Orlandi,Fabio Stagno,Gianni Binotto,Patrizia Pregno,Claudio Fozza,Malgorzata Monika Trawinska,Fiorenza De Gregorio,Daniele Cattaneo,Francesco Albano,Gabriele Gugliotta,Claudia Baratè,Luigi Scaffidi,Chiara Elena,Francesca Pirillo,Emilia Scalzulli,Giorgio La Nasa,Robin Foà,Massimo Breccia +29 more
TL;DR: Patients were stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels, and patients' AOEs were identified.
Journal ArticleDOI
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Giovanni Caocci,Olga Mulas,Mario Annunziata,Luigiana Luciano,Massimiliano Bonifacio,Ester Orlandi,Patrizia Pregno,Sara Galimberti,Antonella Russo Rossi,Elisabetta Abruzzese,Alessandra Iurlo,Bruno Martino,Nicola Sgherza,Gianni Binotto,Fausto Castagnetti,Antonella Gozzini,Claudio Fozza,Monica Bocchia,Anna Sicuranza,Fabio Stagno,Fabio Efficace,Emilio Usala,Fiorenza De Gregorio,Luigi Scaffidi,Chiara Elena,Francesca Pirillo,Claudia Baratè,Malgorzata Monika Trawinska,Daniele Cattaneo,Claudia Labate,Gabriele Gugliotta,Matteo Molica,Giorgina Specchia,Giorgio La Nasa,Robin Foà,Massimo Breccia +35 more
TL;DR: A large real-life cohort of Italian patients with CML treated with a 2TKIs as firstor subsequent-line of treatment was analyzed to evaluate the incidence of CV AEs and the association with the SCORE assessment and other baseline risk factors and the role of primary prophylaxis in preventing CV atherothrombotic events.
Journal ArticleDOI
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors
Giovanni Caocci,Olga Mulas,Mario Annunziata,Luigiana Luciano,Elisabetta Abruzzese,Massimiliano Bonifacio,Ester Orlandi,Francesco Albano,Sara Galimberti,Alessandra Iurlo,Patrizia Pregno,Nicola Sgherza,Bruno Martino,Gianni Binotto,Fausto Castagnetti,Antonella Gozzini,Monica Bocchia,Claudio Fozza,Fabio Stagno,Maria Pina Simula,Fiorenza De Gregorio,Malgorzata Monika Trawinska,Luigi Scaffidi,Chiara Elena,Imma Attolico,Claudia Baratè,Daniele Cattaneo,Francesca Pirillo,Gabriele Gugliotta,Anna Sicuranza,Matteo Molica,Giorgio La Nasa,Robin Foà,Massimo Breccia +33 more
TL;DR: Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered.
Journal ArticleDOI
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice
Giovanni Caocci,Olga Mulas,Elisabetta Abruzzese,Alessandra Iurlo,Mario Annunziata,Ester Orlandi,Sara Galimberti,Gianni Binotto,Nicola Sgherza,Luigia Luciano,Bruno Martino,Antonella Russo Rossi,Massimiliano Bonifacio,Claudio Fozza,Malgorzata Monika Trawinska,Daniele Cattaneo,Chiara Elena,Claudia Baratè,Fiorenza De Gregorio,Matteo Molica,Giorgio La Nasa,Robin Foà,Massimo Breccia +22 more
TL;DR: The SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels.
Journal ArticleDOI
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Olga Mulas,Giovanni Caocci,Fabio Stagno,Massimiliano Bonifacio,Mario Annunziata,Luigiana Luciano,Ester Orlandi,Elisabetta Abruzzese,Nicola Sgherza,Bruno Martino,Francesco Albano,Sara Galimberti,Patrizia Pregno,Monica Bocchia,Fausto Castagnetti,Mario Tiribelli,Gianni Binotto,Antonella Gozzini,Isabella Capodanno,Claudio Fozza,Debora Luzi,Fabio Efficace,Maria Pina Simula,Luigi Scaffidi,Fiorenza De Gregorio,Chiara Elena,Malgorzata Monika Trawinska,Daniele Cattaneo,Imma Attolico,Claudia Baratè,Francesca Pirillo,Anna Sicuranza,Gabriele Gugliotta,Rossella Stella,Emilia Scalzulli,Alessandra Iurlo,Robin Foà,Massimo Breccia,Giorgio La Nasa +38 more
TL;DR: The data suggest that RAS inhibitors may represent an optimal treatment in patients with hypertension and CML, treated with 2nd or 3rd G TKIs, as compared with other drug classes.